Keytruda (pembrolizumab) vs Orserdu (elacestrant)
Keytruda (pembrolizumab) vs Orserdu (elacestrant)
Keytruda (pembrolizumab) is an immune checkpoint inhibitor used to treat various types of cancer by enhancing the body's immune response against cancer cells. Orserdu (elacestrant), on the other hand, is a selective estrogen receptor degrader (SERD) indicated for the treatment of certain types of breast cancer that are estrogen receptor-positive (ER+). When deciding between Keytruda and Orserdu, it is essential to consider the specific type of cancer, its molecular characteristics, and the patient's overall health status, as Keytruda is more broadly used for different cancers, while Orserdu is specifically targeted towards ER+ breast cancer.
Difference between Keytruda and Orserdu
Metric | Keytruda (pembrolizumab) | Orserdu (elacestrant) |
---|---|---|
Generic name | Pembrolizumab | Elacestrant |
Indications | Various cancers including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others | ER+/HER2- advanced or metastatic breast cancer |
Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | Estrogen receptor antagonist |
Brand names | Keytruda | Orserdu |
Administrative route | Intravenous infusion | Oral |
Side effects | Fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain in extremity, and headache | Nausea, vomiting, fatigue, constipation, decreased appetite, and arthralgia |
Contraindications | Severe hypersensitivity to pembrolizumab or any of its excipients | Not provided |
Drug class | Anti-PD-1 monoclonal antibody | Selective estrogen receptor degrader (SERD) |
Manufacturer | Merck & Co. | Radiant Pharmaceuticals |
Efficacy
Keytruda (Pembrolizumab) Efficacy in Breast Cancer
Keytruda, known generically as pembrolizumab, is an immunotherapy drug that has shown efficacy in treating certain types of breast cancer. Specifically, Keytruda has been approved for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1, as determined by an FDA-approved test. Clinical trials have demonstrated that Keytruda, when combined with chemotherapy, can significantly improve progression-free survival compared to chemotherapy alone in these patients. The improvement in overall survival, however, has been more variable and continues to be studied.
Orserdu (Elacestrant) Efficacy in Breast Cancer
Orserdu, also known as elacestrant, is a newer medication that targets estrogen receptor-positive (ER+) breast cancer, which is the most common type of breast cancer. Elacestrant is a selective estrogen receptor degrader (SERD) that works by binding to the estrogen receptor, degrading it, and thus inhibiting the receptor's interaction with estrogen. This mechanism helps to slow down or stop the growth of ER+ breast cancer cells. While Orserdu is still undergoing clinical evaluation, early trial results have shown promise in treating patients with advanced or metastatic ER+ breast cancer, particularly in those who have previously received other hormone therapies.
The efficacy of both Keytruda and Orserdu in breast cancer treatment represents an important advancement in oncology, offering new hope for patients with difficult-to-treat subtypes of the disease. As research continues, the full potential of these drugs in various breast cancer settings will become clearer, potentially leading to expanded indications and improved outcomes for patients.
It is important for patients to discuss the potential benefits and risks of these treatments with their healthcare providers, as the efficacy of Keytruda and Orserdu can vary based on individual patient characteristics and the specifics of their breast cancer diagnosis. Additionally, the use of these medications should be guided by relevant clinical guidelines and the expertise of healthcare professionals specialized in oncology.
Regulatory Agency Approvals
Keytruda
Orserdu
Access Keytruda or Orserdu today
If Keytruda or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us